Cytotoxicity of 2A fractions: 2AFH, 2AFM and 2AFU against HeLa and MRC5-SV2 cells
| 2A Fractions | Cell line | ET (h) | Cell viability (negative control normalised to 100%) | IC50 (μg/mL) | |||
|---|---|---|---|---|---|---|---|
| 10 μg/mL | 50 μg/mL | 100 μg/mL | 200 μg/mL | ||||
| 2AFH | HeLa | 48 | 72.3 ± 2.5*** | 48.7 ± 3.0*** | 39.0 ± 4.9*** | 32.7 ± 4.7*** | 59.4 ± 11.1 |
| 72 | 104.6 ± 3.3 | 59.6 ± 2.8*** | 40.3 ± 3.6*** | 31.2 ± 1.2*** | 84.0 ± 6.1 | ||
| MRC5-SV2 | 48 | 80.4 ± 5.1* | 55.3 ± 4.3*** | 42.1 ± 3.6*** | 33.3 ± 4.0*** | 63.2 ± 12.4 | |
| 72 | 104.3 ± 3.9 | 49.4 ± 6.6*** | 30.3 ± 5.3*** | 21.5 ± 3.5*** | 60.4 ± 11.8 | ||
| 2AFM | HeLa | 48 | 120.6 ± 4.3 | 120.8 ± 6.8 | 109.0 ± 2.4 | 48.2 ± 7.5*** | > 700 |
| 72 | 106.7 ± 5.8 | 111.4 ± 2.0 | 78.9 ± 6.5 | 27.5 ± 3.0*** | 235.0 ± 17.8 | ||
| MRC5-SV2 | 48 | 105.0 ± 3.5 | 115.4 ± 3.7 | 98.9 ± 5.4 | 46.6 ± 11.8*** | > 500 | |
| 72 | 136.3 ± 15.2 | 112.8 ± 1.1 | 100.5 ± 4.2 | 63.0 ± 3.1*** | > 600 | ||
| 2AFU | HeLa | 48 | 74.8 ± 2.0*** | 60.9 ± 2.7*** | 50.1 ± 4.1*** | 41.3 ± 4.3*** | 99.0 ± 14.2 |
| 72 | 79.6 ± 4.6** | 63.0 ± 3.4*** | 49.5 ± 3.3*** | 30.2 ± 3.0*** | 87.0 ± 10.7 | ||
| MRC5-SV2 | 48 | 74.3 ± 3.1*** | 62.1 ± 2.7*** | 54.5 ± 1.9*** | 43.8 ± 0.9*** | 109.0 ± 12.2 | |
| 72 | 106.9 ± 4.4 | 76.7 ± 1.7* | 56.5 ± 4.1*** | 38.5 ± 4.6*** | 146.0 ± 17.5 | ||
* P < 0.05, ** P < 0.01, and *** P < 0.001 indicate a significant difference between the cell viability of treated cells and the cell viability of untreated cells of the negative control wells. ET: exposure time in hours